AZ takes control of Ironwood's IBS drug in China

AstraZeneca has amended a collaboration agreement with Ironwood Pharmaceuticals, gaining sole responsibility for developing, manufacturing and marketing an irritable bowel syndrome drug in

J&J gets Stelara okay in Europe for ulcerative colitis

Lilly moves Crohn's drug into phase 3, faces safety setback ...

Eli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, undercutting a key insulin from Sanofi in the US, but facing safety conce

EU regulators slap safety restriction on Pfizer's Xeljanz

European safety regulators have placed restrictions on Pfizer’s Xeljanz, saying it should not be used in the higher dose in some patients with ulcerative colitis because of concerns of incr

J&J unveils top pipeline prospects, with main focus on cance...

Johnson & Johnson has shone the spotlight on the most promising drugs in its pipeline, saying it plans to file 10 major drugs between now and 2023.

Takeda's Entyvio outperforms AbbVie's Humira in GI trial

Takeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – AbbVie’s Humira – in severely active ulcerative colitis.